One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies ―-Reference-Cited by-同舟云学术

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies ―

Published:2017 Issue:7 Volume:81 Page:1029-1035
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Hirayama Atsushi¹,Yamashita Shizuya²³,Inomata Hyoe⁴,Kassahun Helina⁵,Cyrille Marcoli⁵,Ruzza Andrea⁵,Yoshida Masayuki⁶,Kiyosue Arihiro⁷,Ma Yuhui⁵,Teramoto Tamio⁸

Affiliation:

1. Division of Cardiology, Department of Medicine, Nihon University School of Medicine

2. Departments of Community Medicine and Cardiovascular Medicine, Osaka University Graduate School of Medicine

3. Rinku General Medical Center

4. Amgen Astellas BioPharma K.K.

5. Amgen Inc.

6. Life Science and Bioethics Research Center, Tokyo Medical and Dental University

7. Department of Cardiovascular Medicine, The University of Tokyo Hospital

8. Teikyo Academic Research Center, Teikyo University

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/81/7/81_CJ-16-1016/_pdf

Reference20 articles.

1. 1. Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 2011; 18: 83–88.

2. 2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

3. 3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.

4. 4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

5. 5. Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis 2016; 251: 248–254.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis;Cardiology Research and Practice;2022-04-26

2. Modern Lipid Management: A Literature Review;Cureus;2020-07-24

3. Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial;Journal of Atherosclerosis and Thrombosis;2020-05-01

4. A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab;Case Reports in Hematology;2020-03-26

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

;Therapeutics and Clinical Risk Management;2019-10